The skin is our primary shield against microbial pathogens and has evolved innate and adaptive strategies to enhance immunity in response to injury or microbial insult. The study of antimicrobial peptide (AMP) production in mammalian skin has revealed several of the elegant strategies that AMPs use to prevent infection. AMPs are inducible by both infection and injury and protect the host by directly killing pathogens and/or acting as multifunctional effector molecules that trigger cellular responses to aid in the anti-infective and repair response. Depending on the specific AMP, these molecules can influence cytokine production, cell migration, cell proliferation, differentiation, angiogenesis and wound healing. Abnormal production of AMPs has been associated with the pathogenesis of several cutaneous diseases and plays a role in determining a patient's susceptibility to pathogens. This review will discuss current research on the regulation and function of AMPs in the skin and in skin disorders.
Introduction
Skin is the largest organ of the body and the interface between the environment and our internal biology. It is comprised of three major layers (innermost to outermost): the hypodermis, which is mainly comprised of adipose tissue; the dermis, which consists of connective tissue and contains hair follicles, sebaceous glands and apocrine glands; and the epidermis, which contains squamous cells and basal cells. The upper layer of the epidermis, the stratum corneum, contains keratinocytes that are tightly linked by desmosomes in a hydrophobic cellular matrix and provides a physical barrier against physical, chemical and biological factors [1, 2] . While the dermis is traversed by a network of lymphatic and blood vessels, the epidermis contains antigen-presenting langerhans cells, dendritic epidermal T-lymphocytes, melanocytes, and keratinocytes, the major constituent of the epidermis. All these cells work in concert to provide immune protection against environmental toxic insults, infections and cutaneous neoplasms.
While immunologists in general have tended to focus on leukocytes as the central cell of the immune response, in skin the keratinocyte is an essential and underappreciated part of immunological function. They are the ''first responders'' to external pathogens and serve a critical protective role by forming a physical barrier as well as an immune shield that acts to directly kill microbes. Importantly, however, keratinocytes also play an active and dynamic role to alert the circulating immune system that inflammatory recruitment is required. To accomplish this, the skin produces proinflammatory mediators such as cytokines, chemokines and host defense peptides (antimicrobial peptides; AMPs). In particular, the AMPs are a vital element in skin defense as they are present constitutively, or can be triggered by activation of pattern recognition receptors such as toll-like receptors (TLRs), mannose receptors, helicases, etc. These receptors are responsible for detecting danger signals such as the microbial products lipopolysaccharides (LPS) from Gram-negative bacteria, lipoteichoic acid (LTA) and peptidoglycans from Grampositive bacteria, mannans of yeast and fungi, and nucleic acids from pathogens and self [3] .
As in other tissues, AMPs of the skin are extremely diverse, abundantly expressed and have a broad spectrum of antimicrobial activity as evidenced by their ability to exhibit multifunctional roles in defending against pathogenic insult [4] . AMPs not only directly interact with pathogens but also modulate host immune responses [5] . In keratinocytes, AMPs are mainly synthesized in the stratum granulosum, packaged into lamellar bodies, and then transported to the stratum corneum [6] . In addition to keratinocytes, AMPs are found in the mucosal epithelial tissue and in skin secretions such as saliva and sweat. Furthermore, in neonatal mice and humans, the skin compensates for the lack of a fully developed adaptive immune system by expressing high levels of AMPs that kill Group B Streptococcus [7] . Moreover, during normal skin differentiation, AMPs are induced [8] . The differentiated skin forms the outer permeability barrier that is exposed to the highest number of microbial insults. Collectively, these data highlight the importance of AMPs in regulating our immune biology. This review will discuss the seminal role of AMPs in the immune response to cutaneous infection and in the pathologies of dermatological disease.
Host defense (antimicrobial) peptides
Over 12,000 naturally occurring AMPs have been described or predicted and are present in a wide range of species including plants, insects, animals, and humans [9] [10] [11] . Individually, AMPs function with modest potency; however, in most biological settings, they are co-expressed and act together to directly kill or stop the growth of a widerange of microbial pathogens which include both Grampositive and Gram-negative bacteria, fungi, viruses, and parasites. Most AMPs have an overall net positive charge which ensures their accumulation on, interaction with, and subsequent penetration of the negatively charged phospholipids in the cell walls of microbials [12, 13] . These actions facilitate the killing of microbes. Importantly, microbial resistance to AMPs is low because of difficulties in altering the membrane phospholipid organization. In addition to their direct microbicidal activity, AMPs also upregulate inflammatory cytokines and chemokines to stimulate and recruit other immune mediators, bridging the gap between the innate and adaptive immune system. Despite the evolution of antibiotic resistance, AMPs remain effective natural antibiotics which may be due to their low potency and the absence of one defined, high affinity molecular target [4, 14] . In mammalian skin, a unique set of diverse antimicrobials have been identified that range from these classical pore-forming peptides to larger proteins with alternative functions described before their antimicrobial action was discovered. Table 1 provides a list of these skin AMPs. This review will discuss the actions of cathelicidins and defensins, the two major families of AMPs in the skin, as well as other cutaneous peptides and proteins such as RNase 7, psoriasin, catestatin, and phenol-soluble modulins (PSMs).
Cathelicidins
The first antimicrobial peptide family discovered in mammalian skin was the cathelicidins. Cathelicidins are found in most mammalian species, as well as fish, birds, and snakes [15] . The human cathelicidin gene (CAMP) encodes an 18-kDa a-helical structured precursor protein, known as hCAP-18 that consists of a conserved N-terminal region, cathelin, and a variable carboxy (C-) terminal domain. hCAP-18 is most commonly cleaved to release LL-37, a 37 amino acid peptide that begins with two leucine residues and is the only member of the cathelicidin family of host defense peptides expressed in humans [16, 17] . This processing is carried out by serine proteases, such as kallikrein 5 and 7 in keratinocytes, and by neutrophil proteases, such as serine protease 3, and is required for the diverse biological activity of cathelicidin [18, 19] . LL-37 can be further cleaved in the skin to form different peptides (RK-31, KS-30 and K20) with biological activities that differ from LL-37 [19] . LL-37 is found in neutrophils, natural killer cells, mast cells, and epithelial cells. In addition, it is ubiquitously released in many different tissues such as skin, lung, gut, mammary gland and epididymis.
Mechanisms regulating cathelicidin expression are not completely understood; however, recent advances establish a critical role for 1,25-dihydroxyvitamin D(3) (1,25 D3), the active form of vitamin D3 in epidermal keratinocytes. Stimulation with 1,25 D3 enhances hCAP18 expression in keratinocytes [20] . This form is produced when 1a-hydroxylase (CYP27B1) catalyzes the hydroxylation of 25-hydroxyvitamin D(3) to 1,25 D3. The promoter of the hCAP18 gene contains vitamin D receptor (VDR)-response elements [20] . Upon skin infection and wounding, 1,25 D3 is increased by the local increased expression and activity of CYP27B1 [21] [22] [23] and binds to VDR to stimulate CAMP gene transcription. The precursor of 1,25 D3, vitamin D3 is naturally produced in the skin upon exposure to UV light or deposited after oral ingestion. Cathelicidin expression is also influenced by other factors such as hypoxia inducible factor 1 alpha (HIF-1alpha), the key mediator of the hypoxia response pathway in mammalian cells [24, 25] . Reducing HIF-1alpha protein in human keratinocytes was associated with reduced cathelicidin levels and suppressed immunity to group A Streptococcus pyogenes (GAS) infections [26] . These alternative pathways of regulation appear particularly important in nonhuman species such as mice, as in these normally nocturnal animals the cathelicidin gene does not contain a functional vitamin D response element and is not directly inducible by 1,25 D3.
Defensins
Defensins are a family of low molecular weight (3-5 kDa) AMPs [27, 28] that lack acyl-and glycosyl-side chain modifications, contain arginine residues and have 6 conserved cysteine residues that form intramolecular disulfide bridges to stabilize its triple-stranded beta-sheet structure. The two main defensin families produced in the skin are alpha defensins and beta defensins, differing in the length of peptide segments between the cysteines and the disulfide bond pairs. In the skin, alpha defensins are produced by neutrophils and beta defensins are produced by [60, 61] . In addition, mouse beta-defensin 2 was shown to exhibit adjuvant activity dependent on TLR4 [62] .
Cathelicidins also exhibit chemoattractant activity. In part, LL-37 attracts neutrophils, monocytes, and T cells through binding the formyl peptide receptor-like 1 (FPRL-1) [63] . Similar activity was observed with CRAMP for human monocytes, neutrophils, macrophages, and mouse peripheral blood leukocytes [64] . Furthermore, LL-37 is a chemoattractant for and is produced by mast cells, although the mechanism responsible for this appeared to be independent of FPRL-1 [65] . LL-37 enhanced the expression of costimulatory molecules and Th1 cytokines by monocytederived dendritic cells [66] . Moreover, LL-37 has been shown to promote the release of alpha-defensins from neutrophils [67] , enhance the vascular permeability of mast cells [68] , and stimulate keratinocytes [61] and dendritic cells [60] .
Adding complexity to function, LL-37 has potent effects on TLR responses. LL-37 suppressed LPS-, flagellin-and LTA-induced dendritic cell activation [69] and suppressed LPS-and LTA-induced monocyte and macrophage activation [70, 71] . Furthermore, cathelicidin can act to inhibit TLR4 stimulation. In a model of contact dermatitis, LL-37 inhibited TLR4-and CD44-mediated induction of cytokine release in dendritic cells and macrophages [72] . Hyaluronan, a glycosaminoglycan and alternate TLR4 ligand, activity was attenuated with cathelicidin treatment in a model of chronic allergic dermatitis, and exacerbated in the cathelicidin-deficient mouse Camp-/- [73] . While immunomodulatory functions of AMPs remain unclear, the importance of epithelial AMP function is highlighted by differential AMP levels in dermatological disease states and during wound healing.
AMP production in disease and wound healing

Atopic dermatitis
Atopic dermatitis is an inflammatory pruritic skin disease. A significant portion of patients have abnormalities in the epidermal barrier function and a deficiency in the production of LL-37, hBD2 and hBD3 in lesional skin [33, 74] . In addition to the lower levels of LL-37 and defensins in lesional skin of atopics compared to lesional skin of other inflammatory skin disease such as psoriasis or in wounds, levels of dermcidin are decreased in atopics and in patients with previous bacterial or viral infections [75] . These observations may account for why over 90% of atopics have S. aureus skin colonization which directly correlates with their clinical severity and activates eczema [76, 77] . The reduction in AMPs increases the risk of not only bacterial colonization but also viral infections such as vaccinia and herpes simplex virus [78] [79] [80] .
The reduced levels of AMPs are thought to be caused in part by the heightened Th2 response and overproduction of IL-4, IL-10, and IL-13 [81, 82] . IL-4 and IL-13 directly inhibit hBD2 and hBD3 production in keratinocytes [83] [84] [85] . They can also indirectly inhibit hBD3 and LL-37 by inhibiting STAT6 activation and causing the subsequent inhibition of TNF alpha/NF-jB and IFNgamma [81] [82] [83] 86] .
UVB therapy is frequently used to treat atopic dermatitis. Its therapeutic action is mainly thought to occur by targeting T cell-mediated immune responses [87] . However, UVB also causes the cutaneous activation of vitamin D3 [88] and subsequent upregulation of hCAP18 [89] . Influencing cathelicidin expression may help ameliorate symptoms of atopic dermatitis.
Interestingly, Harder et al.
[37] recently demonstrated enhanced expression of hBD2, hBD3, psoriasin, and RNase 7 in atopic lesional skin when compared with non-lesional skin and controls, suggesting that a disturbed skin barrier may trigger AMP induction in disease. This was also observed in psoriatic patients. Such an increase in AMPs in atopic dermatitis was predicted by earlier studies [74] , as the capacity to increase AMPs is not completely abolished in all patients with atopic dermatitis. In fact, a recent study by Hata et al. [90] has demonstrated that the magnitude of suppressed AMP expression in atopics correlates with disease severity and history of infection. Thus, patients with a history of skin infection were the population with the lowest AMP expression in lesional skin.
Psoriasis
Psoriasis affects up to 3% of the population and is characterized by the formation of typical scaly plaques and hypertrophic skin lesions [91] . In contrast to atopic dermatitis, psoriasis is an inflammatory skin disease with elevated levels of AMPs and a heightened Th1 response [92] . The induction of Th1 cytokines and reduction of Th2 cytokines accounts for the high expression of hBDs in psoriatic patients. In addition, higher genetic copy numbers of beta defensins are associated with psoriasis risk [92] . hBD2 and hBD3 are abundant in psoriatic scales [93, 94] . These plaques are also rich in lysozyme, RNase 7, psoriasin and human neutrophil defensins 1-3 [94] . Cathelicidin levels are also elevated and are thought to exacerbate the disease [95] . The abundance of LL-37 has been proposed to enable patients to react to self-DNA and drive an autoimmune reaction. In this model, human self-DNA, only when Role of skin host defense peptides 2193 complexed with LL-37, activates plasmacytoid dendritic cells (pDCs) through TLR9 [96] . Activation of pDCs initiates the release of IFN-alpha and serves to augment a Th17 inflammatory response. Unlike atopic dermatitis which is frequently accompanied by bacterial infections, in psoriasis, secondary bacterial infections are rare which may be due to the protective effects of elevated AMPs [74] .
Rosacea
Rosacea is common chronic inflammatory skin disease that is characterized primarily by flushing, non-transient erythema, papules, pustules, inflammatory nodules and telangiectasia. Symptoms are often exacerbated by exercise, emotional stress and alcohol [97] . Rosacea is characterized by abnormal AMP expression and processing. Yamasaki et al. [98] showed that individuals with rosacea express elevated levels of cathelicidin. The cathelicidin peptide forms that characterize the disease were found to promote vasoactivation [99] and leukocyte infiltration [63] . Furthermore, mice exhibit an inflammatory response similar to rosacea when administered these cathelicidin peptides [98] . Mechanisms which control cathelicidin production are abnormal in rosacea. Increased activity of kallikrein 5, the protease which controls cathelicidin production, is observed [98] . In addition, some patients with severe rosacea have polymorphisms in their VDR gene [100] , suggesting an increased sensitivity to vitamin D processing of cathelicidin.
Other skin infections
Evidence suggests that the pathogenesis of acne vulgaris and superficial folliculitis may be linked with AMP expression. Inflammatory acne vulgaris affects up to 80% of people and is caused when the overgrowth of Propionibacterium acnes (P. acnes), a Gram-positive anaerobic bacterium residing in pilosebaceous follicles, disrupts the epidermal barrier allowing other bacteria to spread from the microcomedone to the dermis [54] . This translocation of bacteria triggers the production of pro-inflammatory cytokines and granulomatous reactions [101, 102] . In addition, hBD1 and hBD2 are upregulated in the suprabasal layers and in the hair follicle [103] . Similarly, in superficial folliculitis, a skin disease often caused by S. aureus infection and inflammation in the hair follicle, hBD2 is upregulated in lesional skin [104] . Other skin disorders have also been observed to be accompanied by changes in AMP expression. These include higher amounts of hBD2 and lower levels of hBD1 in basal cell carcinoma tumors compared to normal skin [105] , and increased cathelicidin expression in systemic lupus erythematosus [8] . The precise role of AMPs in these skin diseases remains unclear.
Wound healing
The role of defensins and cathelicidin in wound healing has been extensively studied. Low levels of AMPs are present in healthy intact skin whereas cathelicidin and defensin expression are abundant post-wounding and in healing skin epithelia [106] [107] [108] [109] . Our laboratory first discovered that AMPs were present in mammalian skin when we demonstrated that a cathelicidin peptide in wounded pig skin (PR-39) induced syndecans, a cell surface heparin sulfate proteoglycans that regulates cell proliferation and migration [110] . Since that time, several studies have uncovered a wide range of roles for AMPs in addition to their antimicrobial function. For example, hBD2 accelerates wound closure by promoting proliferation, migration, and tube formation of endothelial cells [109] . Similarly, LL-37 accelerates wound closure by promoting proliferation, migration and neovascularization [63, 99] . These findings are consistent with data demonstrating that blocking LL-37 with an antibody inhibits re-epithelialization [107] and that CRAMP -/-mice exhibit decreased vascularization during wound repair [99] . Keratinocyte migration has been shown to be influenced by LL-37-induced transactivation of the epidermal growth factor receptor (EGFR) and activation of STAT1 and STAT3 [111] . This occurs when LL-37 initiates matrix metalloproteinases to cleave the heparinbinding-EGF (HB-EGF) subsequently phosphorylating EGFR [111] . Similarly, LL-37 stimulates EGFR transactivation in corneal epithelial cells under conditions of normal and high glucose [112] . Furthermore, LL-37 induces angiogenesis by activating FPRL-1 expressed on endothelial cells [99] and increases wound closure by activating signaling pathways involved in endothelial proliferation such as MAPK, PI3K and Akt [99, 113] . Interestingly, LL-37 may also accelerate wound healing by attenuating scar tissue formation in dermal fibroblasts by inhibiting transforming growth factor-beta-induced collagen expression in these cells [114] .
Skin ulcers are often due to venous insufficiency and in association with immune diseases such as pyoderma gangrenosum and vasculitis. In patients with non-healing chronic ulcers of the skin, hCAP18 is present at low levels, and LL-37 is absent from the wound edge [107] . hBD3 was found to promote wound closure in a preclinical, largeanimal model of diabetes [115] . These data suggest a therapeutic role for AMPs in successful wound closure. Pexiganan, the frog magainin derivative MSI-78, is a cationic antimicrobial peptide topically administered to patients with diabetic food ulcers and has had significant therapeutic efficacy in 90% of patients [116] . The use of novel clinically useable antimicrobial peptides is currently being investigated in several skin conditions.
Conclusion
Much of our knowledge of how AMPs are regulated and how they function to dampen effects of harmful microbial compounds comes from our study of them in the skin. AMPs have the capacity to directly kill microbes and modulate the immune response. These activities are integral to their promise as novel anti-infective and wound healing agents. Several synthetic AMPs are currently in commercial development [117] . However, the clinical use of these molecules has therapeutic benefits that extend beyond the treatment of skin diseases. Infectious disease remains a leading cause of morbidity and mortality worldwide and presents a major economic burden. While we continue to be faced with pandemics such as HIV/AIDS, new pathogens (such as H1N1) emerge and threaten our survival. The greatest problem facing modern drug discovery is the ability of microorganisms to withstand the effects of antibiotics. Reasons such as these create an urgent need for the development of new antimicrobial drugs that are cheap and effective, and augment defense systems that have naturally evolved in our environment. Understanding the function of AMPs and ways to regulate AMP production will provide insight for alternative therapies to prevent and lessen disease. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 175:1776-1784 61. Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, Nagaoka I, Okumura K, Ogawa H (2007) Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J Invest Dermatol 127:594-604
